Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic Malignancies
Nina Shah(The University of Texas MD Anderson Cancer Center), Krina K. Patel(University of Vermont), Hayder Saeed(University of Kentucky), Mario Q. Marcondes(Nektar Therapeutics (United States)), Mary Tagliaferri(Nektar Therapeutics (United States)), Kazuharu Kai(Nektar Therapeutics (United States)), Alan Tan(Unknown), Lihua E. Budde(City Of Hope National Medical Center), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Cameron J. Turtle(The University of Sydney), Andrew J. Cowan(University of Washington), Mitchell S. Cairo(New York Medical College), Zachary Lee(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 21
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
|Blood|2014|880
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816